Randomized Phase II Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage III-IV) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis.
Amanda N FaderDana M RoqueEric Robb SiegelNatalia BuzaPei HuiOsama AbdelghanySetsuko ChambersAngeles Alvarez SecordLaura HavrileskyDavid M O'MalleyFloor J BackesNicole NevadunskyBabak EdrakiDirk PikaartWilliam LoweryKarim ElSahwiPaul CelanoStefania BelloneMasoud AzodiBabak LitkouhiElena RatnerDan-Arin SilasiPeter E SchwartzAlessandro D SantinPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Addition of T to C/P increased PFS and OS in women with advanced/recurrent HER2/Neu-positive USC, with the greatest benefit seen for the treatment of stage III to IV disease.